AuroBlog - Aurous Healthcare Clinical Trials blog
JULY 10, 2022
A new anti-hangover supplement has just gone on sale in the UK. It is marketed by Swedish firm Myrkl as “the pre-drinking pill that works” The pill is said to break down up to 70 percent of alcohol after 60 minutes. This means that if someone drinks 50 ml of 40 percent spirits, which contains […].
BioSpace
JULY 10, 2022
Scientists found that SARS-CoV-2 spike protein in the plasma could be a hallmark of long COVID, suggesting that the virus can linger in the body who suffer from prolonged symptoms.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
AuroBlog - Aurous Healthcare Clinical Trials blog
JULY 10, 2022
The Union ministry of health and family welfare has issued the final notification amending the rule by which liquid antiseptics for household use were brought under the Schedule K of Drugs Rules, 1945, to exempt it from certain conditions till November 30, 2022. The inclusion of liquid antiseptics under the Schedule K was subject to […].
BioSpace
JULY 10, 2022
A silicon wafer offers the powerful insights of the human genome for the low price of $100. Ultima Genomics CEO Gilad Almogy discussed the therapeutic possibilities with BioSpace.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Scienmag
JULY 10, 2022
HRH The Duchess of Gloucester will today officially open the Heart and Lung Research Institute (HLRI), a major new addition to the Cambridge Biomedical Campus. Credit: Royal Papworth Hospital HRH The Duchess of Gloucester will today officially open the Heart and Lung Research Institute (HLRI), a major new addition to the Cambridge Biomedical Campus.
BioSpace
JULY 10, 2022
Imago's early failed experiments investigating the potential of LSD1 in sickle cell disease and thalassemia have turned out to be fortuitous for patients with myeloproliferative neoplasms.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
BioSpace
JULY 10, 2022
Vertex Pharmaceuticals plans to acquire ViaCyte for $320 million in cash. ViaCyte focuses on stem cell-derived cell replacement therapies that they hope will cure type 1 diabetes (T1D).
Scienmag
JULY 10, 2022
Paris, France – July 11, 2022: As incredible as it may seem, there are trillions on tiny organisms living in, on, and around us. Healthy amounts of tiny creatures like bacteria and fungi in parts of our bodies, like our guts, help ensure that things run smoothly. Our gut is a highly complex region that […].
BioSpace
JULY 10, 2022
Exelixis' Cabometyx, in combination with two BMS-owned drugs, hit the primary endpoint of progression-free survival but missed the secondary endpoint of overall survival in renal cell carcinoma.
Scienmag
JULY 10, 2022
Speaking the same language as their physician can make for healthier patients, new research using ICES data confirms. Frail, older patients admitted to hospital who received care from physicians who spoke their primary language had shorter hospital stays, fewer falls and infections, and were less likely to die in hospital, according to a new study […].
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
BioSpace
JULY 10, 2022
The experimental drug, being developed to treat immunoglobulin A nephropathy, is IONIS-FB-L Rx, which hit the mark in a Phase II study showing a change in urinary protein after 29 weeks of treatment.
Scienmag
JULY 10, 2022
For health care providers who may be caring for Ukrainians displaced by the war, a new analysis published in CMAJ (Canadian Medical Association Journal) provides an overview of health and clinical considerations in this population. It also highlights the key gaps in the Canadian health care systems that need to be addressed to deliver equitable […].
BioSpace
JULY 10, 2022
Tonix Pharmaceuticals announced a mid-stage study for major depressive disorder, which followed the June disclosure of a Phase II study for a cocaine intoxication therapy.
Trialfacts
JULY 10, 2022
Contents. About the Study. Why Participate? Your Rights. Who Can Participate? More Study Details. About the Research Center: Location. Research Center: National Intrepid Center of Excellence (NICoE). Location: 4860 South Palmer Road, Bethesda, MD 20889. Lead Researcher: Chandler Rhodes, Ph.D. IRB: This study has been reviewed and approved by the Walter Reed National Military Medical Center Institutional Review Board.
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
BioSpace
JULY 10, 2022
Weeks after BridgeBio presented positive biomarker data in Canavan Disease, gene therapy company Myrtelle added its own data to the emerging research space.
Drug Patent Watch
JULY 10, 2022
Annual Drug Patent Expirations for ULESFIA Ulesfia is a drug marketed by Shionogi Inc and is included in one NDA. There are two patents protecting this drug and one Paragraph…. The post New patent expiration for Shionogi Inc drug ULESFIA appeared first on DrugPatentWatch - Make Better Decisions.
BioSpace
JULY 10, 2022
Innoviva Inc. and La Jolla Pharmaceutical Company announced Monday that they had entered into a $149-million merger agreement.
Scienmag
JULY 10, 2022
10 July 2022. Robert C. Malenka, M.D., Ph.D, Pritzker Professor of Psychiatry and Behavioural Sciences, Stanford University (US) has been awarded the Peter Seeburg Integrative Neuroscience Prize 2022 for his ground-breaking research in identifying the mechanically distinct forms of synaptic plasticity present in the human brain. His work has helped to distinctly separate the steps […].
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
BioSpace
JULY 10, 2022
The study was assessing the investigational drug enoblituzumab as part of a combination therapy for head and neck cancer.
BioTech 365
JULY 10, 2022
The global bladder cancer drugs market is expected to grow from $1.98 billion in 2021 to $2.35 billion in 2022 at a compound annual growth rate (CAGR) of 19.1%. The market is expected to reach $4.
BioSpace
JULY 10, 2022
The latest Employment Situation report from the Bureau of Labor Statistics shows that employment for healthcare workers is slowly but surely returning to its pre-pandemic levels.
Drug Patent Watch
JULY 10, 2022
This chart shows the pharmaceutical companies with the most powder dosed drugs. For a different perspective, see the most popular dosage types. The companies with the most powder dosed drugs…. The post Which pharmaceutical companies have the most powder dosed drugs? appeared first on DrugPatentWatch - Make Better Decisions.
Advertisement
As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.
BioSpace
JULY 10, 2022
Ayala announced positive data for its desmoid tumor treatment, while Vertex and Dyne announced the FDA had lifted the hold on their clinical studies.
BioSpace
JULY 10, 2022
HRA Pharma, a Perrigo company, has submitted an application to the FDA seeking approval for the country’s first-ever over-the-counter (OTC) birth control pill.
Expert insights. Personalized for you.
224 
Let's personalize your content